Program targeting Pseudomonas aeruginosa
Multidrug-resistant Gram-negative infections
Pre-clinicalActive
Key Facts
Indication
Multidrug-resistant Gram-negative infections
Phase
Pre-clinical
Status
Active
Company
About Telum Therapeutics
Telum Therapeutics is a private, preclinical-stage biotech addressing the global antimicrobial resistance (AMR) crisis. Its core innovation is the APEXp® platform, which uses synthetic biology and AI to engineer phage lytic enzymes as targeted alternatives to traditional antibiotics. The company's pipeline targets high-priority, multidrug-resistant Gram-negative and Gram-positive pathogens, positioning it in a critical and growing market. As a pre-revenue entity, its success hinges on advancing its lead programs through clinical validation and securing strategic partnerships or funding.
View full company profileTherapeutic Areas
Other Multidrug-resistant Gram-negative infections Drugs
| Drug | Company | Phase |
|---|---|---|
| OMPTA LPS & BamA Program | Spexis | Pre-clinical |
| OMPTA LptA Thanatin Program | Spexis | Pre-clinical |
| Program targeting Enterobacteriaceae | Telum Therapeutics | Pre-clinical |
| Program targeting Acinetobacter baumannii | Telum Therapeutics | Pre-clinical |
| BAL2420 | Basilea Pharmaceutica | Phase 1 |